Search

Displaying results 2801 - 2810 of 6835 in total
  1. Indication

    Actinic Keratosis (AK)

    go.drugbank.com/conditions/DBCOND0065881
    Drugs: Diclofenac · Fluorouracil · Hyaluronic acid · Ingenol mebutate · Nitrogen · Salicylic acid
    Synonyms: (Dermatoses NOS) or (solar keratosis) or (seborrhoeic wart), (Actinic keratosis) or (seborrhoeic wart) or (other dermatoses NOS)
  2. Drug

    Amisulpride

    go.drugbank.com/drugs/DB06288
    ApprovedInvestigational

    [A6755] Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents. … In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of

    Synonyms: 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide
  3. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

  4. Drug

    Decamethonium

    go.drugbank.com/drugs/DB01245
    Approved

    Decamethonium is used in anesthesia to cause paralysis. It is a short acting depolarizing muscle relaxant. … It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.

  5. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the … [A262061] Although resistance to multiple TKI has been reported, including [crizotinib], [lorlatinib], [taletrectinib], and [entrectinib], there has been no reported case of repotrectinib resistance.

  6. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1.

  7. Drug

    Teplinovivint

    go.drugbank.com/drugs/DB21475
    Experimental

    The usage of the INN stem '-vivint' in the name indicates that Teplinovivint is a Wnt signaling inhibitor. Teplinovivint has a monoisotopic molecular weight of 442.21 Da.

  8. Drug

    Ipivivint

    go.drugbank.com/drugs/DB21479
    Experimental

    The usage of the INN stem '-vivint' in the name indicates that Ipivivint is a Wnt signaling inhibitor. Ipivivint has a monoisotopic molecular weight of 464.19 Da.

  9. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.

  10. Drug

    Eugenol

    go.drugbank.com/drugs/DB09086
    ApprovedInvestigational

    Eugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves. … Its exact mechanism of action is unknown, however, it has been shown to interfere with action potential conduction.